Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers |
| |
| Authors: | Erik B Dam Marco Loog Claus Christiansen Inger Byrjalsen Jenny Folkesson Mads Nielsen Arish A Qazi Paola C Pettersen Patrick Garnero and Morten A Karsdal |
| |
| Institution: | (1) Nordic Bioscience, Herlev Hovedgade 207, 2730 Herlev, Denmark;(2) Department of Computer Science, Universitetsparken 1, University of Copenhagen, 2100 Copenhagen, Denmark;(3) Faculty of Electrical Engineering, Mathematics, and Computer Science, Delft University of Technology, Mekelweg 4, 2628, CD, Delft, The Netherlands;(4) Center for Clinical and Basic Research, Ballerup Byvej 222, 2750 Ballerup, Denmark;(5) CCBR-Synarc, Molecular Markers, Rue Montbrillant 16, 69003 Lyon, France |
| |
| Abstract: | Introduction At present, no disease-modifying osteoarthritis drugs (DMOADS) are approved by the FDA (US Food and Drug Administration);
possibly partly due to inadequate trial design since efficacy demonstration requires disease progression in the placebo group.
We investigated whether combinations of biochemical and magnetic resonance imaging (MRI)-based markers provided effective
diagnostic and prognostic tools for identifying subjects with high risk of progression. Specifically, we investigated aggregate
cartilage longevity markers combining markers of breakdown, quantity, and quality. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
